ACSS2-Mediated Metabolic-Epigenetic Crosstalk Drives Fulvestrant Resistance and Represents a Novel Therapeutic Target
Ayca Nazli Mogol, Jin Young Yoo, Alicia Arredondo Eve, Mahima Goel, David J Dutton, Claire P. Schane, Audrey Lam, Debapriya Dutta, Betsy Barnick, Eda D. Erdogan, Erik Russell Nelson, Maria Grosse-Perdekamp, Zeynep Madak‐Erdogan
This study identifies ACSS2-mediated metabolic-epigenetic crosstalk as a driver of Fulvestrant resistance in ER+ breast cancer and presents ACSI as a potential therapeutic target.
npj Breast Cancer · Jun 27, 2026Peer-reviewedCancer Biology